Health Canada approved Vraylar as monotherapy for the acute management of manic, mixed, and depressive episodes associated with bipolar I disorder in adults, as well as treatment of schizophrenia in adults, Richter said.

Cariprazine, also sold under the brand Reagila, was Richter's top-selling product last year, generating a turnover of close to HUF 107 billion.